EAM
PMVP icon

Exome Asset Management’s PMV Pharmaceuticals PMVP Stock Holding History

Exome Asset Management’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-358,400
Closed -$581K – 76
2024
Q2 		$581K Buy
+358,400
New +$646K 0.52% 44

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Exome Asset Management's PMVP Position: Q3 2024 in Review

Exome Asset Management sold out of PMV Pharmaceuticals (PMVP) in Q3 2024, closing a stake of 358,400 shares — an estimated $581K sold.

Exome Asset Management first reported a position in PMVP in Q2 2024 and held it in 1 quarter. The position peaked at $581K in Q2 2024. 74 funds tracked by Wall St. Rank hold PMVP as of Q3 2024.

  • Exome Asset Management reported no remaining PMV Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Exome Asset Management sold 358,400 PMV Pharmaceuticals shares in Q3 2024, an estimated $581K.
  • Exome Asset Management first reported a position in PMV Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Exome Asset Management's PMV Pharmaceuticals position peaked at $581K in Q2 2024.
  • 74 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q3 2024.

Based on Exome Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.